Meta‑Flux closed a $2 million seed round to build a platform that integrates multiomics, neural networks and biological modeling to forecast therapeutic and safety outcomes preclinically. The company, operating between Cambridge, MA and Dublin, says the technology will bridge gaps between preclinical findings and clinical performance. CEO Lee Sherlock framed the raise as funding to validate predictive workflows that could reduce late‑stage failures and accelerate candidate prioritization.